Fermion Raises Hundreds of Millions of Yuan in Series A

AI new drug company Fermion has completed a total of hundreds of millions of yuan financing in series , this round of investors include Panda Capital, Guangzhou Financial Holdings, Tongsheng Capital, etc. This round of financing funds will be mainly used for team upgrades, improvement of technical models and data models, and the expansion of the number of related product pipeline cooperation.

Fermion was established in 2018, focusing on the development of an AI-assisted pharmaceutical technology platform for small molecule chemical drugs. Through cooperation with CRO companies and original pharmaceutical companies, it uses AI technologies such as deep learning, reinforcement learning, generation confrontation, big data, and knowledge graphs. To improve the efficiency of early research and development of new drugs.

At present, Fermion has self-developed FermiNet small molecule R&D platform based on deep learning, which can cover the whole process from target to PCC preclinical candidate compound, and can automatically generate small molecules with similar physical and chemical properties to existing target active compounds. It is important to know that the discovery and optimization of lead compounds is crucial in the overall development of new drugs. High-quality active lead compounds can greatly shorten the time for drug discovery and increase the possibility of drug development.

According to reports, from the selection of the target to the PCC stage, the current technology using Fermion can save 1-2 years compared to the traditional pharmaceutical company's research and development, and some of the optimization links can increase the efficiency by more than 10 times compared with the traditional method.

In recent years, with the continuous deepening of the normalization of centralized procurement and the cancellation of the proportion of drugs, the living space of generic pharmaceutical companies has been compressed, and many domestic pharmaceutical companies have to seek innovation and independently develop new drugs. However, the long development cycle of new drugs, low success rate and high R&D costs are still obstacles that many pharmaceutical companies cannot overcome in reality.

Nowadays, AI brings new ideas and methods to multiple links in drug discovery. Artificial intelligence technology represented by deep learning can accelerate the research and development of medicines and increase the success rate of drug research and development by virtue of its powerful ability to discover relationships and computing capabilities.